What is it about?
In longitudinal settings, we analyzed neuroimaging and single nucleotide polymorphism datasets obtained from the Alzheimer’s Disease Neuroimaging Initiative for three clinical stages of the disease, including healthy control, early mild cognitive impairment and Alzheimer’s disease subjects. We conducted a GWAS regressing the absolute change of global connectivity metrics on the genetic variants, and used the GWAS summary statistics to compute the gene and pathway scores.
Photo by Robina Weermeijer on Unsplash
Why is it important?
Although methods have been proposed for integrating image characteristics and genetic information for studying Alzheimers, the measurement of disease is often taken at a single time point, therefore, not allowing the disease progression to be taken into consideration.
Read the Original
This page is a summary of: Genome-Wide Association Study of Brain Connectivity Changes for Alzheimer’s Disease, Scientific Reports, January 2020, Springer Science + Business Media, DOI: 10.1038/s41598-020-58291-1.
You can read the full text:
The following have contributed to this page